Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Financial Bull 3X Shares ETF
FAS
SPDR S&P Retail ETF
XRT
4
iShares US Home Construction ETF
ITB
5
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
CN Stock MarketDetailed Quotes
Jiangsu Hengrui Pharmaceuticals (600276)
- 47.88
- -0.61-1.26%
Market Closed Jun 15 15:00 CST
317.79BMarket Cap39.15P/E (TTM)
48.80High47.62Low669.41KlotVolume48.44Open48.49Prev Close3.22BTurnover1.05%Turnover Ratio41.20P/E (Static)6.64BShares73.8452wk High5.10P/B305.43BFloat Cap45.2652wk Low53.34Limit Up6.38BShs Float96.31Historical High43.64Limit Down2.43%Range %-1.35Historical Low0.20Dividend TTM48.10Avg Price350.30KlotAsk0.42%Div Yield TTM100Lot Size283.82KlotBid
600276 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
600276 Orderflow
Unit: --
600276 Orderflow Trend
IntradayDayWeekMonth
No Data
Jiangsu Hengrui Pharmaceuticals (600276) News
Hong Kong Market Moves | Most innovative drug-related stocks rise as industry BD deals remain robust; policy support and the logic of commercial profitability realization remain intact
Most innovative drug-related stocks rose, with Kelun-Biotech (06990) up 8.62% to HK$428.4 and RemeGen (09995) up 8.11% to HK$75.3.
On June 11, Hengrui Pharma (01276) repurchased 150,000 A-shares at a cost of RMB 7.0335 million.
Hengrui Pharma (01276) announced that on June 11, 2026, it repurchased 150,000 A-shares at a cost of RMB 7.0335 million.
Zhitong AH Statistics | June 11
AH Statistics | June 11
UBS Keeps Their Buy Rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)
Hengrui Pharma (600276.SH): HRS-6209 capsules and two other drug candidates have been approved to commence clinical trials.
Hengrui Pharma (600276.SH) announced that the company and its subsidiaries, Shandong Shengdi Pharmaceutical Co., Ltd. and Guangdong Hengrui Pharmaceutical Co., Ltd., have recently received the "Notice of Approval for Drug Clinical Trials" from the National Medical Products Administration regarding HRS-6209 capsules, HRS-8080 tablets, and HRS-9813 capsules, and will initiate clinical trials shortly.
On June 9, Hengrui Pharma (01276) repurchased 70,000 A-shares at a cost of RMB 3.1936 million.
Hengrui Pharma (01276) announced that on June 9, 2026, the company repurchased 70,000 A-shares at a total cost of RMB 3.1936 million, with a repurchase price range of RMB 45.30 to RMB 45.82 per share.
Jiangsu Hengrui Pharmaceuticals (600276) Stock Forum
$HENGRUI PHARMA (01276.HK)$
Fundamental Check
• Sales growth: TTM revenue ~RMB31bn, growing ~18–19% YoY, driven by innovative drug sales.
• Balance sheet: Healthy leverage with D/E ~0.3–0.4, indicating low financial risk.
• Cash flow: FCF is positive, but growth is still somewhat uneven due to sustained high R&D investment.
From a valuation perspective, this is where I become cautious. At current prices, TTM P/S is ~13–14x, which already reflects high growth expectations. For pharma names, I gen...
Fundamental Check
• Sales growth: TTM revenue ~RMB31bn, growing ~18–19% YoY, driven by innovative drug sales.
• Balance sheet: Healthy leverage with D/E ~0.3–0.4, indicating low financial risk.
• Cash flow: FCF is positive, but growth is still somewhat uneven due to sustained high R&D investment.
From a valuation perspective, this is where I become cautious. At current prices, TTM P/S is ~13–14x, which already reflects high growth expectations. For pharma names, I gen...
1
$HENGRUI PHARMA (01276.HK)$ 53.00 is like the great wall of china for today. it's moving in tandem with A-share. Waiting for it to drop <50.
1
The decline in EPS has likely disappointed the market, making investors hesitant to buy. Despite the recent share price increase, the long-term performance has been less impressive, significantly under-performing the market.
1
Jiangsu Hengrui Medicine's high P/E ratio is backed by its promising earnings outlook. Investors retain the stock, expecting a bright future. The risk of earnings decline is not seen as substantial enough to justify a lower P/E ratio, bolstering the share price.
$Jiangsu Hengrui Pharmaceuticals (600276.SH)$ will hold to the day turn around!
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)